About Polycythemia Vera (PV)
Knowing your PV symptoms and blood
counts can help you stay ahead of
possible disease progression
JAKAFI® or JAKAFI XR™ (ruxolitinib) is a prescription medication used to treat adults with polycythemia vera (PV) who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it. It is not known if JAKAFl or JAKAFl XR is safe or effective in children for treatment of polycythemia vera.
Knowing your PV symptoms and blood
counts can help you stay ahead of
possible disease progression
PV is a rare, chronic blood cancer in which a person’s body makes too many red blood cells, white blood cells, and/or platelets. PV is part of a group of diseases called myeloproliferative neoplasms, or MPNs.
Too many red blood cells can cause the blood to thicken. Thicker blood doesn’t flow normally through veins and may lead to the formation of blood clots.
The exact cause of PV is unknown, but proteins known as Janus kinases, or JAKs, are involved. JAK proteins send signals that help control how many blood cells your body makes. This is called normal signaling.
In PV, JAKs send too many signals, causing the body to make too many blood cells. This is called overactive signaling.
PV is often linked to changes in the JAK2 gene, which can cause overactive signaling that triggers inflammation and other symptoms. A blood test can help identify these gene changes.
PV affects everyone differently, and some symptoms may be difficult to recognize. Learning about common PV symptoms can help you know what to look for and when to speak up to your doctor.
If something doesn’t feel right, or if you’re not sure whether a symptom is related to PV, talk to your doctor as soon as possible.
Fatigue
(feeling very tired)
Night sweats
(excessive sweating during sleep)
Itching
(often after bathing)
Bone pain
Unintentional weight loss
Inactivity
Fever over 100° F
Concentration problems
Pain under the left ribs
If you are currently taking hydroxyurea (HU), there are certain aspects of your PV that you may want to discuss with your doctor when considering a change to your treatment.
If you notice any changes in your blood counts or spleen size, or if you can’t do the things that you used to do because you don’t feel well enough, talk to your doctor. If HU isn’t keeping your PV under control, JAKAFI® or JAKAFI XR™ (ruxolitinib) may be a possible treatment option for you.
See how IncyteCARES helps eligible patients with access and support.
Fill out the form and get helpful information and specialized support just for you.
JAKAFI® or JAKAFI XR™ (ruxolitinib) can cause serious side effects, including:
Low blood counts: JAKAFI or JAKAFI XR may cause low platelet, red blood cell, and white blood cell counts. If you develop bleeding, stop taking JAKAFI or JAKAFI XR and call your healthcare provider. Your healthcare provider will do a blood test to check your blood counts before you start and regularly during your treatment. Your healthcare provider may change your dose or stop your treatment based on the results of your blood tests.
Tell your healthcare provider right away if you develop or have worsening symptoms such as
Infection: You may be at risk for developing a serious infection during treatment with JAKAFI or JAKAFI XR. Tell your healthcare provider if you develop any of the following symptoms of infection:
JAKAFI® or JAKAFI XR™ (ruxolitinib) is a prescription medication used to treat adults with certain types of myelofibrosis (MF).
It is not known if JAKAFI or JAKAFI XR is safe or effective in children for treatment of myelofibrosis.
JAKAFI or JAKAFI XR is a prescription medication used to treat adults with polycythemia vera (PV) who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.
It is not known if JAKAFI or JAKAFI XR is safe or effective in children for treatment of polycythemia vera.
JAKAFI or JAKAFI XR is a prescription medication used to treat adults and children 12 years of age and older with acute graft-versus-host disease (GVHD) who have taken corticosteroids and they did not work well enough.
JAKAFI or JAKAFI XR is a prescription medication used to treat adults and children 12 years of age and older with chronic graft-versus-host disease (GVHD) who have taken one or two types of treatments and they did not work well enough.
Worsening of symptoms after interrupting or stopping treatment. Signs and symptoms of myelofibrosis may worsen after you stop treatment.
Do not interrupt or stop treatment without talking to your healthcare provider. Tell your healthcare provider right away if you have any of the following after stopping treatment:
Cancer: Some people have had certain types of non-melanoma skin cancers during treatment with JAKAFI or JAKAFI XR. Your healthcare provider will regularly check your skin during your treatment. Tell your healthcare provider if you develop any new or changing skin lesions during treatment.
Increases in cholesterol: You may have changes in your blood cholesterol levels during treatment with JAKAFI or JAKAFI XR. Your healthcare provider will do blood tests to check your cholesterol levels about every 8 to 12 weeks after you start taking JAKAFI or JAKAFI XR and as needed.
Increased risk of major cardiovascular events such as heart attack, stroke or death in people who have cardiovascular risk factors and who are current or past smokers while using another JAK inhibitor to treat rheumatoid arthritis:
Get emergency help right away if you get any symptoms of a heart attack or stroke during treatment with JAKAFI or JAKAFI XR, including:
Increased risk of blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) have happened in people taking another JAK inhibitor for rheumatoid arthritis and may be life-threatening.
Tell your healthcare provider right away if you have any signs and symptoms of blood clots during treatment with JAKAFI or JAKAFI XR, including:
Possible increased risk of new (secondary) cancers: People who take another JAK inhibitor for rheumatoid arthritis have an increased risk of new (secondary) cancers, including lymphoma and other cancers. People who smoke or who smoked in the past have an added risk of new cancers.
The most common side effects of JAKAFI or JAKAFI XR include:
These are not all the possible side effects. Ask your pharmacist or healthcare provider for more information. Call your doctor for medical advice about side effects.
Before taking JAKAFI or JAKAFI XR, tell your healthcare provider about:
Women should not take JAKAFI or JAKAFI XR while pregnant or planning to become pregnant. Do not breastfeed during treatment with JAKAFI or JAKAFI XR and for 2 weeks after the final dose.
How should I take JAKAFI or JAKAFI XR?
Please see the Full Prescribing Information and Patient Information, which include a more complete discussion of the risks associated with JAKAFI or JAKAFI XR.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
You may also report side effects to Incyte Medical Information at 1-855-463-3463.